[A19-29] Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2019
Commission awarded on 29.03.2019 by the Federal Joint Committee (G-BA).
Monotherapy for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection
Disadvantages in side effects do not completely call into question the advantages in recurrence; overall hint of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.